A trial investigating partial withdrawal of heart failure therapy in patients with heart failure in remission.
EU CTIS ID: 2025-522560-32-01
What this study is testing
To investigate the safety and feasibility of heart failure therapy down-titration versus therapy continuation in patients with heart failure in remission.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adults aged ≥ 18 years
- Heart failure in remission, defined as heart failure with an improved ejection fraction to an LVEF above 50%, with normalized LV volumes, an NT-proBNP ≤ 250 pg/mL, normal functional capacity, and clinical stability
- Patients must receive at least 3 HF therapies (ACEi/ARB/ARNI, BB, and MRA or SGLT2i) for HF, consistent with international HF guidelines. Each therapy must have been titrated to the maximally tolerated dose, stable for at least 6 months prior to screening
You likely can't join if
- Albuminuric chronic kidney disease
- Recent major cardiovascular events such as an acute coronary syndrome, CABG, stroke or TIA in the 90 days before screening
- Uncontrolled hypertension
- Atrial fibrillation or atrial flutter with a resting heart rate >110 beats per minute
- Patients with a cardiac resynchronization therapy device who have < 98% biventricular pacing during screening
- Any sustained ventricular arrythmias within 6 months prior to screening
See the full eligibility criteria
- Adults aged ≥ 18 years
- Heart failure in remission, defined as heart failure with an improved ejection fraction to an LVEF above 50%, with normalized LV volumes, an NT-proBNP ≤ 250 pg/mL, normal functional capacity, and clinical stability
- Patients must receive at least 3 HF therapies (ACEi/ARB/ARNI, BB, and MRA or SGLT2i) for HF, consistent with international HF guidelines. Each therapy must have been titrated to the maximally tolerated dose, stable for at least 6 months prior to screening
- Albuminuric chronic kidney disease
- Recent major cardiovascular events such as an acute coronary syndrome, CABG, stroke or TIA in the 90 days before screening
- Uncontrolled hypertension
- Atrial fibrillation or atrial flutter with a resting heart rate >110 beats per minute
- Patients with a cardiac resynchronization therapy device who have < 98% biventricular pacing during screening
- Any sustained ventricular arrythmias within 6 months prior to screening
- Any untreated valvular heart disease of moderate or greater severity during screening.
- Presence of any other disease with a life expectancy of < 2 years.
- Pregnant or lactating women.
The study team makes the final eligibility decision.
Where it's taking place
- Belgium
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Belgium. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.